BACKGROUND: In sub-Saharan Africa, rates of sustained HIV virologic suppression remain below international goals. HIV resistance testing, while common in resource-rich settings, has not gained traction due to concerns about cost and sustainability. OBJECTIVE: We designed a randomized clinical trial to determine the feasibility, effectiveness, and cost-effectiveness of routine HIV resistance testing in sub-Saharan Africa. APPROACH: We describe challenges common to intervention studies in resource-limited settings, and strategies used to address them, including: (1) optimizing generalizability and cost-effectiveness estimates to promote transition from study results to policy; (2) minimizing bias due to patient attrition; and (3) addressing ethical issues related to enrollment of pregnant women. METHODS: The study randomizes people in Uganda and South Africa with virologic failure on first-line therapy to standard of care virologic monitoring or immediate resistance testing. To strengthen external validity, study procedures are conducted within publicly supported laboratory and clinical facilities using local staff. To optimize cost estimates, we collect primary data on quality of life and medical resource utilization. To minimize losses from observation, we collect locally relevant contact information, including Whatsapp account details, for field-based tracking of missing participants. Finally, pregnant women are followed with an adapted protocol which includes an increased visit frequency to minimize risk to them and their fetuses. CONCLUSIONS: REVAMP is a pragammatic randomized clinical trial designed to test the effectiveness and cost-effectiveness of HIV resistance testing versus standard of care in sub-Saharan Africa. We anticipate the results will directly inform HIV policy in sub-Saharan Africa to optimize care for HIV-infected patients.
BACKGROUND: In sub-Saharan Africa, rates of sustained HIV virologic suppression remain below international goals. HIV resistance testing, while common in resource-rich settings, has not gained traction due to concerns about cost and sustainability. OBJECTIVE: We designed a randomized clinical trial to determine the feasibility, effectiveness, and cost-effectiveness of routine HIV resistance testing in sub-Saharan Africa. APPROACH: We describe challenges common to intervention studies in resource-limited settings, and strategies used to address them, including: (1) optimizing generalizability and cost-effectiveness estimates to promote transition from study results to policy; (2) minimizing bias due to patient attrition; and (3) addressing ethical issues related to enrollment of pregnant women. METHODS: The study randomizes people in Uganda and South Africa with virologic failure on first-line therapy to standard of care virologic monitoring or immediate resistance testing. To strengthen external validity, study procedures are conducted within publicly supported laboratory and clinical facilities using local staff. To optimize cost estimates, we collect primary data on quality of life and medical resource utilization. To minimize losses from observation, we collect locally relevant contact information, including Whatsapp account details, for field-based tracking of missing participants. Finally, pregnant women are followed with an adapted protocol which includes an increased visit frequency to minimize risk to them and their fetuses. CONCLUSIONS: REVAMP is a pragammatic randomized clinical trial designed to test the effectiveness and cost-effectiveness of HIV resistance testing versus standard of care in sub-Saharan Africa. We anticipate the results will directly inform HIV policy in sub-Saharan Africa to optimize care for HIV-infectedpatients.
Authors: Calvin J Cohen; Susan Hunt; Michael Sension; Charles Farthing; Marcus Conant; Susan Jacobson; Jeffrey Nadler; Werner Verbiest; Kurt Hertogs; Michael Ames; Alex R Rinehart; Neil M Graham Journal: AIDS Date: 2002-03-08 Impact factor: 4.177
Authors: Cristina Tural; Lidia Ruiz; Christopher Holtzer; Jonathan Schapiro; Pompeyo Viciana; Juan González; Pere Domingo; Charles Boucher; C Rey-Joly; Bonaventura Clotet Journal: AIDS Date: 2002-01-25 Impact factor: 4.177
Authors: Mary A Foulkes; Christine Grady; Catherine Y Spong; Angela Bates; Janine A Clayton Journal: J Womens Health (Larchmt) Date: 2011-08-05 Impact factor: 2.681
Authors: Bruce R Schackman; Sue J Goldie; Kenneth A Freedberg; Elena Losina; John Brazier; Milton C Weinstein Journal: Med Decis Making Date: 2002 Jan-Feb Impact factor: 2.583
Authors: Paula M Luz; Bethany L Morris; Beatriz Grinsztejn; Kenneth A Freedberg; Valdilea G Veloso; Rochelle P Walensky; Elena Losina; Yoriko M Nakamura; Michael P Girouard; Paul E Sax; Claudio J Struchiner; A David Paltiel Journal: J Acquir Immune Defic Syndr Date: 2015-02-01 Impact factor: 3.731
Authors: Zahra Reynolds; Suzanne M McCluskey; Mahomed Yunus S Moosa; Rebecca F Gilbert; Selvan Pillay; Isaac Aturinda; Kevin L Ard; Winnie Muyindike; Nicholas Musinguzi; Godfrey Masette; Pravi Moodley; Jaysingh Brijkumar; Tamlyn Rautenberg; Gavin George; Brent A Johnson; Rajesh T Gandhi; Henry Sunpath; Vincent C Marconi; Mwebesa Bosco Bwana; Mark J Siedner Journal: HIV Med Date: 2021-11-09 Impact factor: 3.094
Authors: Mark J Siedner; Mahomed-Yunus S Moosa; Suzanne McCluskey; Rebecca F Gilbert; Selvan Pillay; Isaac Aturinda; Kevin Ard; Winnie Muyindike; Nicholas Musinguzi; Godfrey Masette; Melendhran Pillay; Pravikrishnen Moodley; Jaysingh Brijkumar; Tamlyn Rautenberg; Gavin George; Rajesh T Gandhi; Brent A Johnson; Henry Sunpath; Mwebesa B Bwana; Vincent C Marconi Journal: Ann Intern Med Date: 2021-10-26 Impact factor: 51.598
Authors: Rahel E Bircher; Alex J Ntamatungiro; Tracy R Glass; Dorcas Mnzava; Amina Nyuri; Herry Mapesi; Daniel H Paris; Manuel Battegay; Thomas Klimkait; Maja Weisser Journal: PLoS One Date: 2020-01-13 Impact factor: 3.240
Authors: Kerlly J Bernabé; Mark Siedner; Alexander C Tsai; Vincent C Marconi; Richard A Murphy Journal: Open Forum Infect Dis Date: 2022-03-09 Impact factor: 3.835
Authors: T A Rautenberg; G George; M B Bwana; M S Moosa; S Pillay; S M McCluskey; I Aturinda; K Ard; W Muyindike; P Moodley; J Brijkumar; B A Johnson; R T Gandhi; H Sunpath; V C Marconi; M J Siedner Journal: J Med Econ Date: 2020-01-11 Impact factor: 2.448